Skip to content

Study · Animal study (in vivo) · mouse · 2015

3 results

Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation.

Binsfeld M, Hannon M, Otjacques E, Humblet-Baron S, Baudoux E, Beguin Y, Baron F, Caers J

Cancer immunology, immunotherapy : CII14 May 2015Cited by 3 (Europe PMC)

PMID25971542 (opens in a new tab)PMCIDPMC11028767 (opens in a new tab)DOI10.1007/s00262-015-1708-2 (opens in a new tab)PepBankPUB-25971542
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In two immunocompetent murine multiple myeloma models, thymosin alpha‑1 administration had no impact on myeloma development.

    In plain wordsIn mice, thymosin alpha‑1 did not change how myeloma developed in two models.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeMultiple myeloma development in vivo
    Study

    mousen: not reported in source

    Immunocompetent murine MM models (5TGM1 and MOPC315.BM)
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, using two immunocompetent murine MM models (5TGM1 and MOPC315.BM), we did not observe any impact of Tα1 administration on MM development in vivo.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In immunodeficient mice transfused with human hematopoietic stem cells, thymosin alpha‑1 treatment had no beneficial effect on lymphocyte immune reconstitution.

    In plain wordsIn mice given human stem cells, thymosin alpha‑1 did not help the immune system recover.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeLymphocyte immune reconstitution after human stem cell transfusion
    Study

    mousen: not reported in source

    Immunodeficient mice given human hematopoietic stem cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, no beneficial effects of Tα1 treatment were observed on lymphocyte immune reconstitution after transfusion of human hematopoietic stem cells into immunodeficient mice.
  3. 03LabIn vitro (cells)Efficacy outcome

    In vitro, thymosin alpha‑1 slightly reduced the proliferation of murine and human multiple myeloma cell lines.

    In plain wordsIn lab tests, thymosin alpha‑1 slightly slowed the growth of mouse and human myeloma cells.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseMultiple myeloma cell line proliferation in vitro
    Study

    mouse and humann: not reported in source

    Murine and human multiple myeloma cell lines
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this study, we observed a slight reduction in the proliferation of murine and human MM cell lines in the presence of Tα1 in vitro.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.